• We are available for your help 24/7
  • Email: info@isindexing.com, submission@isindexing.com


Paper Details

Immuno-Multi-Therapy and Prophylaxis Efficacy against COVID-19

Immuno-Multi-Therapy and Prophylaxis Efficacy against COVID-19

Lungu P Anzwal1*, Kalumba A Kambote1, Tshinawej P Mukiny2, Sadiki P Wabula3, Moba C Iselenge3, Bangutulua V Mbezi3, Mokalu S Maope3, Jean-Paul J Gonzalez4, Balaka M Ekwalanga1

Journal Title: Journal of Clinical Immunology AND Microbiology
Abstract


In the context of the current COVID-19 pandemic, strategies for finding effective therapies advocate the so-called “therapeutic repositioning” approach, i.e., the use of existing molecules on the pharmaceutical market, whose toxicity and therapeutic efficacy are known. The immunotherapy proposed in this study consisted to use four well-known components of validated therapeutic drugs, namely: interferon type 1 (IFNα), interferon type 2 (IFNγ), chloroquine (Chloroquine phosphate) and antioxidants (Vitamins A, C, E, trace elements and lycopene). Such non pathogen specific treatment was curative and preventive (i.e., prophylaxis), and expected to enhance the patient’s innate response. A selected cohort consisted of 122 patients tested positive by RT-PCR (SARS-CoV-2 infection). Among them, 89 patients were asymptomatic and 43 symptomatic (COVID-19). Due to the compassionate nature of this therapeutic approach, age, and gender were randomized. Four types of treatment were selected using a multi-therapy approach applied for a duration of five days. Among the medical team in charge of the protocol ten (10) were subjected for prophylactic purposes to a three-day tri-therapy treatment. A total of 132 participants received a multi-therapy treatment as curative treatment (122 patients) and as prevention (10 health workers). All participants were tested for RT-PCR before treatment, all patients tested positive while the health workers tested negative. After two weeks all participants tested negative by RT-PCR. Clinical follow-up showed a total and rapid recovery at the early stage of tri-immunotherapy while repeated RT-PCR testing for the participants with preventive treatment remained negative. Conclusion. Such multi-immunotherapy protocols against SARS-CoV-2 efficacy appear substantial for treatment and potentially efficient for health worker prevention. Due to our limited subject and the compassionate context, all multi-immunotherapy protocols would require a control study to evaluate their efficacy.